Xiuning Le

11.0k citations

168 papers · 3.5k indexed · 4 hit papers · h-index 32

Impact in

Oncology top 1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Pulmonary and Respiratory Medicine 147
- Lung Cancer Treatments and Mutations 140
- Lung Cancer Diagnosis and Treatment 39
- Gastric Cancer Management and Outcomes 13
Oncology 122
- Lung Cancer Research Studies 48
- Colorectal Cancer Treatments and Studies 30
- HER2/EGFR in Cancer Research 26
- Cancer Immunotherapy and Biomarkers 25

Co-authors: John V. Heymach Monique B. Nilsson Tina Cascone Leonard I. Zon David M. Langenau Matthew D. Keefe Jeffery L. Kutok Donna Neuberg
Journals: Journal of Clinical Oncology (35 papers)Journal of Thoracic Oncology (27 papers)Annals of Oncology (21 papers)Cancer Research (14 papers)Clinical Lung Cancer (5 papers)
Partner nations: United States Japan South Korea

In The Last Decade

Xiuning Le

159 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Antibody-drug conjugates in lung cancer: dawn of a new era? 2023 · 80 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 npj Precision Oncology
2023 Heliyon
2022 Clinical Cancer Research
2020 Journal of Thoracic Oncology

Peers

Countries citing papers authored by Xiuning Le

Since Specialization

Citations

This map shows the geographic impact of Xiuning Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiuning Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiuning Le more than expected).

Fields of papers citing papers by Xiuning Le

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiuning Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiuning Le. The network helps show where Xiuning Le may publish in the future.

Co-authors

The 25 scholars most cited alongside Xiuning Le, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xiuning Le Line = papers co-authored together Xiuning Le links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast Oncology and Therapy ·Balázs Halmos, Narjust Florez, Sarah Goldberg, Wade T. Iams, Xiuning Le, Ticiana Leal, Danny T. Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua K. Sabari, Dennis Björk, Nichelle Stigger, Yichuan Xia, Paul Cifuentes, Denise D’Andrea, Farah Shanoon, Andrew L. Johnson, Melissa L. Johnson	2025	0
2	LBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study Annals of Oncology ·Xiuning Le, T.M. Kim, Xiaorong Dong, Herbert H. Loong, Nicolas Girard, Shun Lu, Hye Ryun Kim, B-C. Goh, A. Prelaj, Yun Fang, Lin Wu, Y. Shinno, G. Daniele, T-Y. Yang, G. Ruiter, J. Zhao, Jan C. Brase, Rachel Li, Paolo Grassi, L. Li	2025	0
3	ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib JCO Precision Oncology ·Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Y. Lau, Helena A. Yu	2025	4
4	Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach Clinical Cancer Research ·Taiwo Adesoye, Ecaterina E. Dumbrava, Kanwal Raghav, Ayşegül A. Şahin, Hui Chen, Sunyoung S. Lee, Milind Javle, Shubham Pant, Omar Alhalabi, Xiuning Le, Vicente Valero, Paula R. Pohlmann, Funda Meric‐Bernstam	2025	0
5	PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC Clinical Cancer Research ·Natalie I. Vokes, Xiuning Le, Timothy A. Yap	2024	2
6	Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review Journal of Thoracic Oncology ·Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo	2024	27
7	Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer Therapeutic Advances in Medical Oncology ·Lisha Ye, Wenjing Wang, Huihui Li, Yongling Ji, Xiuning Le, Xiaoling Xu	2024	3
8	AI in drug discovery and its clinical relevance Heliyon ·Rizwan Qureshi, Muhammad Irfan, Taimoor Muzaffar Gondal, Sheheryar Khan, Jia Wu, Muhammad Usman Hadi, John V. Heymach, Xiuning Le, Hong Yan, Tanvir Alam Hit paper breakdown →	2023	125
9	Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer Nature Reviews Clinical Oncology ·Kelsey Pan, Kyle Concannon, Jing Li, Jianjun Zhang, John V. Heymach, Xiuning Le	2023	22
10	HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma JCO Precision Oncology ·Niamh Coleman, Kathrina L. Marcelo, Julia F. Hopkins, Nusrat Khan, Robyn Du, Lingzhi Hong, Edward Park, Binaifer Balsara, Mollie Leoni, Curtis R. Pickering, Jeffrey N. Myers, John V. Heymach, Lee A. Albacker, David S. Hong, Maura L. Gillison, Xiuning Le	2023	17
11	Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4) Journal of Thoracic Oncology ·Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina S. Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina Chiara Garassino, John V. Heymach, Mark A. Socinski, Szu‐Yun Leu, Gajanan Bhat, François Lebel, Xiuning Le	2023	34
12	Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed by Immunotherapy International Journal of Radiation OncologyBiologyPhysics ·Y Sasaki, Ting Xu, S. Koutroumpakis, Ajay Sheshadri, Anita Deswal, Q.N. Nguyen, S. Gandhi, Tina Cascone, Xiuning Le, Mehmet Altan, A.B. Chen, Zhongxing Liao	2023	1
13	1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial Annals of Oncology ·Santiago Viteri, Enriqueta Felip, Frank Griesinger, Marina Chiara Garassino, Hiroshi Sakai, Xiuning Le, Rémi Veillon, Egbert F. Smit, Jo Raskin, Michael Thomas, M-J. Ahn, Soetkin Vlassak, Rolf Bruns, Andreas Johne, Paul K. Paik	2023	3
14	1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088 Annals of Oncology ·Herbert H. Loong, Gennaro Daniele, T-Y. Yang, Ticiana Leal, Kōichi Goto, Yuki Shinno, Kazumi Nishino, Tomohiro Sakamoto, Enriqueta Felip, J.C. Ruffinelli, Natalia Gallot, Zhou Wang, Chen Chen, Barbara J. Brennan, S-F. Pu, Martin Kornacker, Paolo Grassi, Xiuning Le, Daniel Shao-Weng Tan, B-C. Goh	2023	4
15	1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity Annals of Oncology ·Xiuning Le, Jacqulyne Robichaux, Monique B. Nilsson, Veena Ramaswamy, Aravind Ravichandran, Jia Wu, Yasir Y. Elamin, Lingzhi Hong, Hibiki Udagawa, Mark A. Socinski, Gajanan Bhat, François Lebel, Sylvie Vincent, Veronica Bunn, Ziying Su, John W. Lawson, Jason B. Cross, John V. Heymach	2023	2
16	Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review International Journal of Molecular Sciences ·Qasem Al-Tashi, Maliazurina B. Saad, Amgad Muneer, Rizwan Qureshi, Seyedali Mirjalili, Ajay Sheshadri, Xiuning Le, Natalie I. Vokes, Jianjun Zhang, Jia Wu	2023	65
17	IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC Clinical Cancer Research ·Sonia Patel, Monique B. Nilsson, Yan Yang, Xiuning Le, Hai T. Tran, Yasir Y. Elamin, Xiaoxing Yu, Fahao Zhang, Alissa Poteete, Xiaoyang Ren, Li Shen, Jing Wang, Seyed Javad Moghaddam, Tina Cascone, Michael A. Curran, Don L. Gibbons, John V. Heymach	2023	62
18	Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis Cancers ·Jianchao Xue, Bowen Li, Yadong Wang, Zhicheng Huang, Xinyu Liu, Chao Guo, Zhibo Zheng, Naixin Liang, Xiuning Le, Shanqing Li	2022	3
19	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer Cancer Discovery ·Xiuning Le, Rajee Antony, Pedram Razavi, Daniel J. Treacy, Flora Luo, Mahmoud Ghandi, Pau Castel, Maurizio Scaltriti, José Baselga, Levi A. Garraway	2016	97
20	Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish Proceedings of the National Academy of Sciences ·Xiuning Le, David M. Langenau, Matthew D. Keefe, Jeffery L. Kutok, Donna Neuberg, Leonard I. Zon	2007	152

About Xiuning Le

Xiuning Le is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Otorhinolaryngology, having authored 168 papers that have together received 3.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (48 papers), Lung Cancer Diagnosis and Treatment (39 papers), Colorectal Cancer Treatments and Studies (30 papers), HER2/EGFR in Cancer Research (26 papers), Cancer Immunotherapy and Biomarkers (25 papers), Cancer Genomics and Diagnostics (23 papers) and Gastric Cancer Management and Outcomes (13 papers). The work is most often cited by research in Oncology (1.8k citations), Pulmonary and Respiratory Medicine (2.0k citations), Cancer Research (619 citations), Health Informatics (28 citations) and Molecular Biology (1.3k citations). Xiuning Le has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include John V. Heymach, Monique B. Nilsson, Tina Cascone, Leonard I. Zon, David M. Langenau, Matthew D. Keefe, Jeffery L. Kutok, Donna Neuberg, Sonia Patel and Jonathan W. Goldman. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Cancer Research and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact